Plus Therapeutics announced on March 20, 2025, that the U.S. Food and Drug Administration (FDA) conditionally accepted its new proprietary name, REYOBIQ™, for its lead therapeutic candidate, rhenium Re 186 obisbemeda. This marks a significant step in the drug's development.
The establishment of the REYOBIQ™ brand is an important part of preparing for commercialization. It will enable investigators, investors, and potential patients to connect with the rhenium-based radiotherapeutic beyond its chemical identity.
All future communications regarding the generic name rhenium Re 186 obisbemeda will now utilize the proprietary name REYOBIQ™. This move is expected to foster stronger stakeholder engagement and reinforce the promising progress in developing targeted radiotherapeutics for LM and GBM.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.